TachoSil® Versus Standard Haemostatic Treatment of Haemorrhage in Cardiovascular Surgery (TC-023-IM)
Condition: Haemorrhage; Haemostasis; Cardiovascular Surgery
MeSH terms: Hemorrhage
Intervention: fibrinogen (human) + thrombin (human); Standard haemostatic treatment in cardiovascular surgery
Intervention description: Any haemostatic fleece material without additional active coagulation stimulating compounds (primarily Surgicel®)
Intervention MeSH terms: Hemostatics; Thrombin
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 120.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: Surgical treatment of haemorrhage

Summary:

      To demonstrate efficacy and safety of TachoSil® in cardiovascular surgery
    

Eligibility criteria:

        Inclusion Criteria:

        All inclusion criteria must be answered "yes" for a subject to participate in the trial.

        At Screening:

          1. Has the subject given informed consent according to local requirements before any
             trial related activities? A trial related activity is any procedure that would not
             have been performed during the routine management of the subject. In this trial the
             screening is the first trial related activity.

          2. For female subjects of childbearing potential: Is the pregnancy test at screening
             negative?

          3. Does the female subject of childbearing potential use adequate contraception
             (contraceptive pill, contraceptive injection, contraceptive implant or intrauterine
             device)?

          4. Is the subject ≥ 18 years of age?

          5. Is the following planned: An elective surgery on the heart, the ascending aorta or
             arch, requiring cardiopulmonary bypass procedure?

             Intra operative (after primary haemostatic treatment):

          6. Is bleeding from the heart muscle, the pericardium, a major vessel or a vascular bed
             that requires supportive haemostatic treatment present?

          7. Has the area with the most problematic haemorrhage (target area) been identified?
             (please note that this must be done before randomisation).

          8. Is it possible to compress the randomised treatment (TachoSil® or control fleece
             material) for 3 minutes?

        Exclusion Criteria:

        All exclusion criteria must be answered "no" for a subject to participate in the trial.

        At Screening:

          1. Has the subject participated in any other trial with an investigational drug or device
             within 30 days before inclusion in this trial?

          2. Does the subject participate in a clinical trial concomitantly with the present trial?

          3. Is the subject undergoing an emergency operation?

          4. Has the subject a history of allergic reactions after application of human fibrinogen,
             human thrombin and/or collagen of any origin?

          5. Is the subject suffering from known coagulopathy?

          6. Is the subject currently participating or has the subject previously participated in
             the TC-023-IM trial?

          7. Is the female subject pregnant or breast feeding?

             Intra operative (after primary haemostatic treatment):

          8. Has liquid fibrin sealant/glue or TachoSil® been applied?

          9. Has the following occurred: Disseminated intravascular coagulation (DIC), i.e. micro
             vascular bleeding?